title: Neuphoria Says Phase 3 Trial of BNC210 to Treat Social Anxiety Disorder Did Not Meet Primary Endpoint
source: Yahoo
date: 2025-10-20
url: https://finnhub.io/api/news?id=bb1448244d9d8b1f64fb8cd5dcad68152266d49cbba1fab709440743e46261a9
Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of
